Clinical-stage biotech developing CNS therapies from genetic insights
Praxis is a public clinical-stage biopharmaceutical company focused on central nervous system disorders driven by excitation-inhibition imbalance. The hiring velocity is accelerating with 26 roles posted in the last 30 days — dominated by healthcare, data, and engineering talent — alongside active projects in product launch readiness, Salesforce CRM build-out, and pharmacovigilance infrastructure, signaling a company in transition from preclinical research into commercial operations.
Notable leadership hires: Sales Director, Trade Director
Praxis Precision Medicines develops therapies for neurological disorders using two proprietary platforms: Cerebrum (small molecule) and Solidus (antisense oligonucleotide). The company's strategy centers on genetic insights into shared biological targets and circuits that drive disease across rare and more prevalent conditions. Headquartered in Boston and publicly traded, Praxis operates across clinical development, regulatory, and emerging commercial functions. Current operational focus spans product launch readiness, systems integrations (Veeva for regulatory, Salesforce for sales operations), and workforce scaling — with hiring activity extending into Brazil alongside the U.S. market.
Therapies for central nervous system disorders characterized by excitation-inhibition imbalance, using two platforms: Cerebrum (small molecules) and Solidus (antisense oligonucleotides). Focus is on both rare and more prevalent neurological conditions driven by shared genetic mutations.
Regulatory: Veeva (RIM, Submissions, Publishing, Vault, QMS). CRM/operations: Salesforce, Smartsheet, Paycom. Data/analytics: Python, Databricks, Snowflake. Cloud: AWS, Azure. Lab analytics: LC-MS, HPLC, qPCR.
Other companies in the same industry, closest in size
Praxis Precision Medicines, Inc.'s technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.